Sign in
Active, not recruitingEarly phase 1

Lung Transplant HCV, Pilot Study

Key facts

Who runs it
University Health Network, Toronto
Where
Canada1 site in 1 countryChoose a country to see its sites
Trial code
Status
Active, not recruiting
Phase
Early phase 1
People taking part
26 people enrolled
Started
19 Sept 2017
Expected to end
31 May 2027
Type of study
Interventional
Treatments tested
  • Sofosbuvir-velpatasvir (400 mg/100 mg)
  • Ex Vivo Lung Perfusion (EVLP)
Record updated
11 May 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 4 criteriaShow less

Who can take part

  • Recipients listed for single or bilateral lung transplant
  • HCV Nucleic Acid Amplification Testing (NAT) negative
  • Ability to provide written informed consent

Who cannot take part

  • Participation in another interventional clinical trial

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

In this study HCV negative recipients will be transplanted with HCV positive lungs. Investigators will attempt to decrease infectivity rates by performing Normothermic Ex vivo Lung Perfusion (EVLP), which is an approved method of donor lung preservation, assessment and treatment, and could be an excellent platform to reduce/eliminate hepatitis C virus. Patients will be treated by the standard approved direct-acting antivirals (DAAs) if infection occurs. It is planned to enroll 20 patients from the Lung transplant wait list in this study. Patients will be actively followed for 6 months including HCV PCR tests and then for up for 5 years to look for evidence of HCV infection and any liver or extra-hepatic complications, as well as standard post-transplant complications. This will be a single center pilot study.

The group in the trial

  • HCV+ lung transplant to HCV- recipientsTreatment being tested

    HCV+ donor lungs will be treated with Normothermic Ex Vivo Lung Perfusion (EVLP) in order to reduce viral load and minimize risk of HCV transmission. Patients who become viremic defined as at least two consecutive positive samples will receive sofosbuvir/velpatasvir 400 mg/100 mg (Epclusa) for 12 weeks.

    Treatment: Sofosbuvir-velpatasvir (400 mg/100 mg) and Ex Vivo Lung Perfusion (EVLP)

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Lung Transplantation Using Hepatitis C Positive Donors to Hepatitis C Negative Recipients: A Pilot Study
Publications
Record updated
11 May 2026